Vasomotor symptoms and coronary artery calcium in postmenopausal women.

Vasomotor symptoms and coronary artery calcium in postmenopausal women.
复制标题

DOI:
10.1097/gme.0b013e3181e664dc
复制
发表时间:
2010-11
期刊:
Menopause (New York, N.Y.)
影响因子:
--
通讯作者:
Woods NF
Woods NF
中科院分区:
其他
文献类型:
--
作者:
Allison MA;Manson JE;Aragaki A;Langer RD;Rossouw J;Curb D;Martin LW;Phillips L;Stefanick ML;Cochrane BB;Sarto G;Barnhart J;O'Sullivan MJ;Johnson KC;Gass M;Trevisan M;Woods NF

文献摘要

参考文献

被引文献

相似文献

We assessed whether vasomotor symptoms (VMS) were associated with coronary artery calcium (CAC) and how hormone therapy may influence this association. Subjects were a subset of women aged 50 to 59 and a history of hysterectomy that enrolled in the Women’s Health Initiative (WHI) clinical trial of estrogen alone and underwent a computed tomography scan of the chest at the end of the trial to determine CAC. Participants provided information about VMS (hot flashes and/or night sweats), as well as HT use, on self-administered questionnaires at trial baseline. The sample consisted of 918 women with a mean (SD) age of 55.1 (2.8) years at WHI randomization and 64.8 (2.9) years at CAC ascertainment. The prevalence of a CAC score > 0 was 46%, while the prevalence of a CAC score ≥ 10 and > 100 was 39 and 19%, respectively. At randomization, 77% reported a history of any VMS at any time prior to or at enrollment in the WHI while 20% reported any VMS only present at enrollment. Compared to those without a history of any VMS and after adjustment for potential confounders, a history of any VMS at any time up to and including WHI enrollment was associated with a significantly reduced odds for CAC > 0 (Odds Ratio 0.66, 95% CI 0.45 – 0.98). Moreover, as duration of HT increased the inverse association between any VMS and CAC moved toward the null. A history of any VMS was significantly associated with a reduced odds for CAC independent of traditional CVD risk factors and other relevant covariates. This association appears to be influenced by duration of hormone therapy.
DOI: 10.1016/0029-7844(96)00196-2
发表时间: 1996-09-01
影响因子: 7.2
作者:
Guthrie, JR;Dennerstein, L;Burger, HG
通讯作者: Burger, HG
DOI: 10.1161/hq1201.100229
发表时间: 2001-12-01
影响因子: 8.7
作者:
Dhore, CR;Cleutjens, JPM;Daemen, MJAP
通讯作者: Daemen, MJAP
DOI: 10.1016/s0029-7844(02)02369-4
发表时间: 2002-12-01
影响因子: 7.2
作者:
Barnabei, VM;Grady, D;Pickar, JH
通讯作者: Pickar, JH
DOI: 10.1016/s1047-2797(03)00043-7
发表时间: 2003-10-01
影响因子: 5.6
作者:
Anderson, GL;Manson, J;Prentice, RL
通讯作者: Prentice, RL
DOI: 10.1016/j.ijcard.2004.03.015
发表时间: 2005-02-15
影响因子: 3.5
作者:
Allison, MA;Wright, CM
通讯作者: Wright, CM